ELEVATE Trial: Elacestrant Combos Boost PFS in ER+/HER2- Breast Cancer ...
1 day ago · Key Takeaways Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The ELEVATE trial …
The Latest on Emerging Therapies for Metastatic HR+/HER2- Breast Cancer ...
1 day ago · Trials such as SERENA-6 are testing circulating tumor DNA (ctDNA) to guide treatment changes ahead of disease progression in patients with advanced breast cancer.
1 in 4 metastatic breast cancer patients treated with - GlobeNewswire
3 days ago · The post-hoc exploratory analysis of the MONALEESA-2, -3 and -7 trials in first-line HR+/HER2- MBC aimed to identify clinical characteristics and biomarkers of patients who …
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali ...
3 days ago · Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative …
Sacituzumab govitecan-hziy led to similar progression-free survival as ...
2 days ago · "In cases where HR-positive, HER2-negative, metastatic breast cancer has become refractory to endocrine therapy, chemotherapy remains a common standard," she explained.
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 ... - BioSpace
4 days ago · About ORSERDU (elacestrant) U.S. Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER) …
Neratinib Plus Capecitabine for the Treatment of Her2-Negative ...
This phase II trial tests how well neratinib in combination with capecitabine works in treating patients with HER2-negative breast cancer that has spread from where it first started (primary site) to other …
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2
5 days ago · ELCIN (NCT05596409) is a phase 2 trial evaluating the efficacy of elacestrant in patients with ER+, HER2- advanced/metastatic breast cancer who received one or two prior hormonal …
Rapid Guideline Update Supports Capivasertib for Hormone Receptor ...
Apr 25, 2024 · Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer now have a new medication option that extends survival, according to an ASCO rapid guideline update. 1 …
A Phase I Trial of Alpelisib Combined With Capecitabine in ... - PubMed
Abstract Background: Alpelisib is an oral α-specific class I PI3K inhibitor approved in combination with fulvestrant for the treatment of PIK3CA-mutated hormone receptor-positive (HR+), human epidermal …